Could a vitamin pill slow Parkinson's? major trial tests nicotinamide riboside

NCT ID NCT03568968

Completed Disease control Sponsor: Haukeland University Hospital Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This completed Phase 3 trial tested whether a daily supplement called nicotinamide riboside (a form of vitamin B3) can slow the progression of early Parkinson's disease. 410 people with early-stage Parkinson's took either the supplement or a placebo for 52 weeks. Researchers measured changes in motor and non-motor symptoms using a standard rating scale. The goal was to see if replenishing a key cellular energy molecule (NAD) could help protect brain cells.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: nicotinamide riboside (a form of vitamin B3)
What this could lead to: If it works, this could point toward a way to slow the progression of early Parkinson's disease using a simple dietary supplement.
What could go wrong: This is a completed Phase 3 trial, but results are not yet published. The supplement may not slow the disease, and benefits may be small or not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PARKINSON DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Parkinson disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PARKINSON DISEASE

Contacts and locations

Locations

Akershus university hospital

Oslo, Norway
Arendal Hospital

Arendal, Norway
Bodø Hospital

Bodø, Nordland, Norway
Førde sykehus

Førde, Norway
Haugesund Hospital

Haugesund, Norway
Haukeland University Hospital

Bergen, Norway
Molde sjukehus

Molde, Norway
Oslo University Hospital

Oslo, Norway
University Hospital of North Norway

Tromsø, Norway
Vestre Viken Hospital

Drammen, Norway
Østfold Hospital

Fredrikstad, Østland, Norway

More trials for these conditions

Other studies related to the condition(s) this trial covers.